Sponsors / VRCA
VRCA

Verrica Pharmaceuticals Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
6Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Cantharidin and Occlusion in Verruca EpitheliumNCT03487549VRCAPhase 2Completed2019-05-16Actual
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsNCT03981822VRCAPhase 2Completed2020-05-21Actual
Open-Label Proof of Concept Study of VP-315 in Basal Cell CarcinomaNCT05188729VRCAPhase 2Completed2024-04-15Actual
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)NCT07246590VRCAPhase 3Recruiting2027-06Estimated
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)NCT07457918VRCAPhase 3Recruiting2028-04-30Estimated
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)NCT07637734VRCAPhase 3Recruiting2027-05Estimated

Latest recorded trial changes